Sun Pharma to Acquire Organon in $11.75 Billion All-Cash Deal, Creating a Global Pharma Leader with $12.4 Billion in Combined Revenue

On April 27, 2026, Sun Pharmaceutical Industries Ltd., India’s largest pharmaceutical company, and Organon & Co., a global healthcare company, jointly announced that they had signed a definitive merger agreement.Sun Pharmaceutical will acquire all outstanding shares of Organon in an all-cash transaction at $14.00 per share, valuing Organon’s enterprise value at $11.75 billion (approximately RMB 80.2 billion).

The transaction has currently received approval from the boards of directors of both parties and remains subject to customary closing conditions, including regulatory approvals and shareholder approval from Organon. It is expected to be formally completed in early 2027. As a rare large-scale cross-border merger and acquisition by an Indian pharmaceutical company in recent years, this deal will not only facilitate resource complementarity between the two enterprises but also have a profound impact on the global pharmaceutical landscape and the transformation of India’s pharmaceutical industry.

Organon, established in 2021 as a spin-off from Merck & Co. (known as MSD outside the United States and Canada), is a multinational company focused on global healthcare. Headquartered in Jersey City, New Jersey, USA, it is listed on the New York Stock Exchange (ticker symbol: OGN).

As a global leader in women’s health, the company has remained steadfast in its mission to “deliver impactful medicines and solutions that help people enjoy healthier everydays” since its inception, building a strong foundation of trust and robust brand equity among healthcare professionals, patients, regulatory authorities, and other stakeholders.

In terms of business layout,Organon has built a product portfolio spanning two core areas—women’s health and established medicines—comprising more than 70 products, including biosimilars. These products are widely used in scenarios such as women’s health management and the treatment of common diseases, with its core products enjoying high recognition in global markets. In terms of market coverage, Organon operates in more than 140 countries and regions, with the United States, Europe, China, Canada, and Brazil serving as its key markets. Its robust global commercialization network provides strong support for product launch and market access.

Production and Financial Levels,Organon operates six manufacturing bases across the European Union and emerging markets, with scaled and standardized production capabilities that effectively support its global business operations. Financial data shows that for the fiscal year ended December 31, 2025, Organon generated $6.2 billion in revenue and achieved an adjusted EBITDA of $1.9 billion. During the same period, the company’s total debt stood at $8.6 billion, with a cash balance of $574 million. Additionally, Organon recently completed a product divestiture transaction, receiving a $440 million upfront payment. This infusion will further bolster its cash reserves, ensuring business stability during the transition period of the transaction.

It is worth noting that, prior to the completion of this transaction, Organon will continue to operate independently, with its strategic focus and ongoing projects remaining unaffected. These initiatives include the five-year update for Nexplanon, the global launch and promotion of VTAMA, the market introduction of Miudella, and the continued expansion of its biosimilar portfolio. Meanwhile, the company’s leadership team will remain in place to ensure a smooth business transition.

As India’s largest pharmaceutical company and one of the top ten generic drug manufacturers globally, Sun Pharmaceutical has demonstrated a clear strategic orientation in its recent M&A activities. These efforts center on three core pillars: strengthening innovation capabilities, expanding global presence, and addressing gaps in its product portfolio. This strategy is gradually enabling the company’s transformation from a generics-focused player to an innovator in novel drugs, and from a regional market participant to a global competitor.

A review of Sun Pharma’s recent M&A activities reveals a clearly targeted acquisition strategy: the 2023 acquisition of U.S.-based Concert Pharmaceuticals further strengthened its innovative drug R&D pipeline; the 2025 purchase of U.S. oncology company Checkpoint Therapeutics for $355 million expanded its portfolio of innovative products in oncology and dermatology; and the current acquisition of Organon represents its largest and most geographically diverse overseas M&A deal to date, marking a new phase in its globalization strategy.

From the perspective of M&A logic,Sun Pharmaceutical has consistently adhered to the principle of “complementary M&A,” focusing on its areas of weakness to rapidly acquire core resources, technologies, and market channels through mergers and acquisitions. Previously, Sun Pharma’s core strengths were concentrated in generics, dermatology, ophthalmology, and innovative drugs for oncology-dermatology, with innovative pharmaceutical products accounting for approximately 20% of its sales. However, the company had significant shortcomings in women’s health, biosimilars, established branded medicines, and global commercialization networks. Organon’s business layout is highly complementary to these weaknesses, which constitutes the core rationale behind this acquisition.

The strategic significance of this acquisition is particularly prominent for Sun Pharma. Upon completion of the transaction, Sun Pharma will achieve multiple breakthroughs:

Rank among the top 25 global pharmaceutical companies, with combined revenue reaching $12.4 billion; become a leading player in the mature brands/branded generics segment while transforming into a company more focused on innovative drugs, with the share of innovative drug revenue increasing to 27%; successfully rank among the top three globally in women’s health and as the seventh-largest biosimilar manufacturer worldwide, addressing core gaps in the product portfolio; expand business coverage to 150 countries, with annual revenues exceeding $100 million in each of 18 major markets, further enhancing global presence; additionally, post-merger EBITDA and cash flow will nearly double, helping reduce the net debt-to-EBITDA ratio to 2.3x after the transaction, achieving deleveraging targets and strengthening financial stability.

From the perspective of industry development,This transaction is not only a landmark event in the transformation of India’s pharmaceutical industry but also reflects the consolidation trend within the global pharmaceutical sector. For a long time, India’s pharmaceutical industry has been defined by generic drugs. In recent years, however, supported by government policies and increased R&D investment, Indian pharmaceutical companies have been accelerating their transition toward innovative drugs and biologics. Sun Pharma’s acquisition is a concrete manifestation of this transformation at the corporate level. For the global pharmaceutical industry, leading enterprises have increasingly turned to mergers and acquisitions (M&A) to integrate resources and optimize product portfolios, serving as a key strategy to cope with pressure from centralized procurement and enhance core competitiveness. The combination of Sun Pharma and Organon will further increase market concentration in areas such as women’s health, biosimilars, and generic drugs.

Furthermore, this transaction offers a new reference paradigm for global pharmaceutical M&A: executing large-scale acquisitions through all-cash payments to balance transaction efficiency with shareholder interests, while emphasizing post-transaction business continuity and the realization of synergies. Given the current scarcity of innovative drugs in the field of women’s health—according to Nature Reviews Drug Discovery, only 7% of new drugs approved by the FDA over the past 16 years targeted diseases exclusive to women, a figure that drops to 3% when oncology drugs are excluded—Sun Pharma’s strategic entry into the women’s health sector through the acquisition of Organon is poised to drive R&D investment and product innovation, thereby filling critical gaps in the industry.